Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Press release
Herantis Pharma Plc | Press Release | February 24, 2025 at 10:15 a.m. EET
Herantis Pharma: Invitation to Full Year 2024 report webinar on March 6, 2025
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease will webcast the 2H and Full Year 2024 results, Thursday March 6 at 14:30 EET (13:30 CET). The presentation will be held by CEO Antti Vuolanto and CFO Tone Kvåle, followed by a Q&A session.
Herantis will release the 2H and Full Year 2024 Report on March 6 at 8:00 EET (7:00 CET). The report will be made available online at www.herantis.com.
Please use the following link to register for this event: https://herantis.videosync.fi/q4-2024
After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event.
Following the webcast of the live call, a recording will be available on Herantis Pharma’s website: https://herantis.com/news-events/video-presentations/
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Ltd
Tel: +358 9 25 380 225
Email: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The Phase 1a clinical trial, completed in late 2023, demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com